Objective: To explore the mechanism of Caowu-Hezi in the treatment of rheumatoid arthritis (RA) by network pharmacology and molecular docking technology. Methods: Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and literature were used to screen the effective components of Caowu-Hezi. The potential targets of the effective components were screened by Swiss Target Prediction and other databases. Based on authoritative databases such as OMIM, RA-related potential target data sets were screened. Venny online tool was used for target intersection analysis, and the screening results were imported into Cytoscape 3.7.2 software to construct protein-protein interaction networks (PPI). Gene ontology (GO) functional annotation and Kyoto encyclopedia of genes and genomics (KEGG) pathway enrichment analysis of key targets were performed through the online analysis platform. Finally, Autodock Tools molecular docking software was used to verify the molecular docking of key target proteins and potential active compounds. Results: A total of 16 active components were identified and 109 potential targets related to RA were screened out. Among them, the key targets were signal transduction and transcriptional activator protein 3 (1,STAT3), Toll-like receptor 4 (2,TLR4), transcription factor JUN, interleukin-6 (3,IL-6) and serine protein kinase (4,AKT1). Bioinformatics analysis showed that Toll-like receptor signaling pathway, tumor necrosis factor (5,TNF) signaling pathway and PI3K-Akt signaling pathway might be involved in the regulation of the pathological process of RA. Molecular docking experiments confirmed that the active components of Caowu-Hezi had high binding affinity with the above core targets (such as STAT3, TLR4, JUN, etc.), suggesting its potential regulatory role. Conclusion: Caowu-Hezi may affect the activity of target proteins such as AKT1, JUN, IL-6, STAT3 and TLR4 by regulating key signaling pathways such as Toll-like receptor, TNF and PI3K-Akt, thus exerting anti-RA effect.
ZHU Junxuan
,
ZHANG Dong
,
AN Ming
,
XU Nanbing
,
FANG Longlong
,
WU Guodong
. The mechanism of Caowu-Hezi in thetreatment of rheumatoid arthritis based on network pharmacology and molecular docking technology[J]. Journal of Baotou Medical College, 2026
, 42(4)
: 8
-14
.
DOI: 10.16833/j.cnki.jbmc.2026.04.002
[1] Aihaiti Y, Song Cai Y, Tuerhong X, et al. Therapeutic effects of naringin in rheumatoid arthritis: network pharmacology and experimental validation[J]. Front Pharmacol, 2021, 12: 672054-672054.
[2] 练剑锋. 温针灸联合中药汤剂治疗类风湿性膝关节炎疗效观察[J]. 山西中医, 2015, 31(10):34, 36.
[3] 温志华. 类风湿性关节炎发病机制的临床研究进展[J]. 临床医学, 2022, 42(7): 123-125.
[4] 刘志敏. 那如-3巴布剂的透皮吸收特性及改善大鼠佐剂性关节炎病变的机理[D]. 北京: 北京中医药大学, 2005.
[5] 张学泉. 借鉴蒙医使用草乌的经验[J]. 甘肃中医, 1993, (5): 39.
[6] 陈理, 李峰, 吴仁奇. 草乌、诃子、荜茇的功效与生命元素的关系[J]. 中国民族医药杂志, 1999, (S1): 120.
[7] 杨德志, 胡日查, 特木其乐. 蒙药巴特日-7作用机制的研究现状与展望[J]. 内蒙古大学学报(自然科学版), 2022, 53(4): 439-447.
[8] Li S, Zhang B. Traditional Chinese medicine network pharmacology:theory,methodology and application[J]. Chin J Nat Med, 2013, 11(2): 110-120.
[9] Amberger JS, Bocchini CA, Schiettecatte F, et al. OMIM.org:Online Mendelian Inheritance in Man (OMIM®),an online catalog of human genes and genetic disorders[J]. Nucleic Acids Res, 2015, 43(Database issue): D789-D798.
[10] 梁欣仪, 梅志刚, 闻晓东. 基于数据挖掘的四妙丸类方临床应用配伍规律分析[J]. 中草药, 2022, 53(2): 507-518.
[11] Szklarczyk D, Gable AL, Nastou KC, et al. Correction to′ The STRING database in 2021:customizable protein-protein networks,and functional characterizationof user-uploaded gene/measurement sets′[J]. Nucleic Acids Res, 2021, 49(18): 10800.
[12] Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)[J]. Nucleic Acids Res, 2022, 50(W1): W216-W221.
[13] Berman HM, Westbrook J, Feng Z, et al. The protein data bank[J]. Nucleic Acids Res, 2000, 28(1): 235-242.
[14] 陈扬, 王昭懿, 代一航, 等. 基于网络药理学及分子对接的川乌、草乌配伍治疗类风湿性关节炎机制研究[J]. 世界中西医结合杂志, 2021, 16(6): 1036-1043.
[15] Hsin KY, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology[J]. PLoS One, 2018, 8(12): e83922.
[16] Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis-immune cell-fibroblast-bone interactions[J]. Nat Rev Rheumatol, 2022, 18(7): 415-429.
[17] Siegel RJ, Singh AK, Panipinto PM, et al. Extracellular sulfatase-2 is overexpressed in rheumatoid arthritis and mediates the TNF-α-induced inflammatory activation of synovial fibroblasts[J]. Cell Mol Immunol, 2022, 19(10): 1185-1195.
[18] Tu J, Chen W, Fang Y, et al. PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes[J]. Ann Rheum Dis, 2022, 82(2): 198-211.
[19] 邓毅凡, 张晶, 周玮. 类风湿关节炎合并冠心病患者冠状动脉病变程度与白细胞介素-6、白细胞介素-17水平的相关性[J]. 实用临床医药杂志, 2022, 26(3): 55-58.
[20] 闫慧明, 张雪, 安燕, 等. 分子信号通路在类风湿关节炎发病机制中的研究进展[J]. 风湿病与关节炎, 2020, 9(9): 76-80.
[21] Zhao Y, Sun X, Lin J, et al. Panaxynol induces fibroblast-like synovial cell apoptosis,inhibits proliferation and invasion through TLR4/NF-κB pathway to alleviate rheumatoid arthritis[J]. Int Immunopharmacol, 2021, 101(PA): 108321.
